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OBJECTIVEdCoronary artery disease (CAD) is the major cause of morbidity and mortality in
type 2 diabetic patients. Severe vitamin D deﬁciency has been shown to predict cardiovascular
mortality in type 2 diabetic patients.
RESEARCH DESIGNANDMETHODSdWe investigated the association among severe
vitamin D deﬁciency, coronary calcium score (CCS), and asymptomatic CAD in type 2 diabetic
patients with elevated urinary albumin excretion rate (UAER) .30 mg/24 h. This was a cross-
sectional study including 200 type 2 diabetic patients without a history of CAD. Severe vitamin D
deﬁciency was deﬁned as plasma 25-hydroxyvitamin D (p-25[OH]D3) ,12.5 nmol/L. Patients
with plasmaN-terminal pro-brain natriuretic peptide.45.2 ng/L or CCS$400were stratiﬁed as
being high risk for CAD (n = 133). High-risk patients were examined by myocardial perfusion
imaging (MPI; n = 109), computed tomography angiography (n = 20), or coronary angiography
(CAG; n = 86). Patients’ p-25(OH)D3 levels were determined by high-performance liquid
chromatography/tandem mass spectrometry.
RESULTSdThe median (range) vitamin D level was 36.9 (3.8–118.6) nmol/L. The prevalence
of severe vitamin D deﬁciency was 9.5% (19/200). MPI or CAG demonstrated signiﬁcant CAD in
70 patients (35%). The prevalence of CCS$400 was 34% (68/200). Severe vitamin D deﬁciency
was associated with CCS $400 (odds ratio [OR] 4.3, 95% CI [1.5–12.1], P = 0.005). This
association persisted after adjusting for risk factors (4.6, 1.5–13.9, P = 0.007). Furthermore,
severe vitamin D deﬁciency was associated with asymptomatic CAD (adjusted OR 2.9, 1.02–7.66,
P = 0.047).
CONCLUSIONSdIn high-risk type 2 diabetic patients with elevated UAER, low levels of
vitamin D are associated with asymptomatic CAD.
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Coronary artery disease (CAD) is themajor cause of morbidity and mor-tality in patients with type 2 diabe-
tes. Diabetic patients have been shown to
have an increased prevalence of subclin-
ical CAD (1). Coronary calcium score
(CCS), a noninvasive screening method
quantifying the extent of coronary artery
calciﬁcation (CAC), is generally accepted
as a marker of increased cardiovascular
risk. CCS has been shown to correlate
strongly with histopathologic CAD (2,3)
and the development of adverse coronary
events (4,5).
Results from cross-sectional studies
examining the relation between low vi-
tamin D levels and presence of CAD in the
general population are conﬂicting (6,7).
In type 1 diabetic patients, vitamin D de-
ﬁciency has been shown to independently
predict both prevalence and development
of CAC (8). However, a study in type 2
diabetic patients with a history of cardio-
vascular disease (CVD) found a strong in-
verse association between low vitamin D
levels and prevalent coronary, cerebro-
vascular, or peripheral CVD (9). Further-
more, low vitamin D levels have been
associated with increased cardiovascular
morbidity and mortality in the general
population (10) and in patients with
type 1 (8) and 2 (11) diabetes.
To expand our knowledge on the in-
creased all-cause and cardiovascular mor-
tality seen in type 2 diabetic patients with
low vitamin D levels, the current study
investigated the association between severe
vitamin D (plasma 25-hydroxyvitamin D
[p-25(OH)D3]) deﬁciency and the pres-
ence of elevated CAC and asymptomatic
CAD in type 2 diabetic patients with
elevated urinary albumin excretion rate
(UAER) .30 mg/24 h.
RESEARCH DESIGN AND
METHODSdIn a cross-sectional study
at Steno Diabetes Center from January
2007 to February 2008, we identiﬁed a
cohort of 200 type 2 diabetic patients
without prior diagnosed CAD or other
known cardiac disease but with a high
risk of CAD as indicated by persistent
UAER.30 mg/24 h. A written invitation
to participate in the study was sent to all
patients aged 20–70 years from the out-
patient clinic (n = 613, 69% were male,
patients had a mean [SD] age of 47 [8]
years). Seventy-two patients refused to
participate. Patients were excluded (n =
341) if one or more of the following char-
acteristics were present: normal UAER or
nonpersistent elevated UAER, signiﬁcant
Q-waves in the 12-lead electrocardiogram,
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and relative contraindications to com-
puted tomography angiography or coro-
nary angiography (CAG), including
elevated plasma creatinine above the upper
normal limit. All patients received multi-
factorial treatment for the prevention
of CAD. The treatment included statins
(94%), aspirin (90%), and blockade of
the renin-angiotensin-aldosterone system
(98%). The p-25(OH)D3 levels were de-
termined by high-performance liquid
chromatography/tandem mass spectrom-
etry. Severe vitamin D deﬁciency was de-
ﬁned as p-25(OH)D3 ,12.5 nmol/L in
correspondence with the National Danish
guidelines at the time of the study. Plasma
N-terminal pro-brain natriuretic peptide
(p-NT-proBNP) was analyzed by an im-
munoassay as previously described (12).
Clinical measurements and results of the
cardiac examinations have been described
(13) and are therefore only outlined brieﬂy
in the current article. Coronary calcium
scanning was performed during a single
breath-hold using a 16 multidetector-
row computed tomography scanner with
3-mm slice thickness with quantiﬁcation
of Agatston CCS (Heartbeat-CS, EBW;
Philips Medical Systems, Andover, MA)
(14). According to levels of p-NT-proBNP
and CCS, patients were stratiﬁed into
groups with high or low risk for CAD
in the following manner: 1) Patients with
p-NT-proBNP .45.2 ng/L (this cutoff
value was the median p-NT-proBNP
among the ﬁrst 50 patients examined) or
CCS $400 were deﬁned as high risk (n =
133). 2) All other patients were considered
low risk, i.e., patients assumed not to have
CAD (n = 67). High-risk patients were ex-
amined by myocardial perfusion imaging
(MPI) (n = 109), computed tomography
angiography (n = 20), or CAG (n = 86),
according to our study referral algorithm
for patients with abnormal results of the
noninvasive tests for further invasive ex-
amination (13). MPI was performed
using a standard 2-day protocol with
99mTc-Tetrofosmin (600–900 MBq) in-
jected at rest and at peak stress with intra-
venous dipyridamole (0.6 mg/kg over 4
min). CAG was performed according to
standard techniques. Coronary artery ste-
nosis was deﬁned as left main stem lumi-
nal diameter stenosis .50% or luminal
stenosis.70% of the left anterior descend-
ing, right, or left circumﬂex coronary artery.
Elevated CAC was deﬁned by CCS $400.
Signiﬁcant CAD was deﬁned as the pres-
ence of one or more signiﬁcant myocardial
perfusion defects on MPI or one or more
signiﬁcant major epicardial coronary artery
stenoses on CAG. All patients had normal
p-creatinine levels and no recent illnesses
or history of liver disease. The study was
approved by the local ethics committee,
and all patients gave written informed
consent.
Statistical analysis
Variables with skewed distribution are
expressed as medians (interquartile range);
data for all other variables are expressed
as means (SD). Non-normally distributed
variables were log10-transformed before
analysis. Because CCS was highly skewed
with values of zero, log10 (CCS + 1) was
used for analysis. The patients were divided
into two groups, in accordance with a vita-
min D level$ or,12.5 nmol/L. Compar-
isons between groups were performed
using an unpaired Student t test. The Pear-
son x2 test was used to compare non-
continuous variables. The association of
severe vitamin D deﬁciency with the pres-
ence of signiﬁcant CAD or CCS$400 was
assessed by logistic regression model and
expressed as unadjusted and adjusted
odds ratio (OR) with 95% CIs. Covariate
adjustments were made for sex, age, and
conventional cardiovascular risk factors
(systolic blood pressure, p-total cholesterol,
p-creatinine, and smoking). Two-tailed
P values#0.05 were considered statistically
signiﬁcant. All statistical calculations were
performed using SPSS for Windows, ver-
sion 14.0 (SPSS Institute, Inc., Chicago, IL).
RESULTSdThe clinical baseline patient
characteristics are shown in Table 1.
Median (range) vitamin D level was 36.9
(3.8–118.6) nmol/L. The prevalence of
severe vitamin D deﬁciency was 9.5%
(19/200). In linear regression analyses,
vitamin D level was negatively associated
with BMI (R = 20.26, P , 0.01), and a
weak positive association was found with
age (R = 0.159, P = 0.025). Vitamin D
levels were not associated with sex, blood
pressure, HbA1c, estimated glomerular
ﬁltration rate (eGFR), and UAER. Further-
more, neither eGFR nor UAER was asso-
ciated with CCS scores or prevalence of
signiﬁcant CAD.
The prevalence of CCS $400 was
34% (68/200). Twelve of 68 patients
(18%) with elevated CCS had severe
vitamin D deﬁciency. In contrast, only 6
of 132 patients (4.5%) with CCS ,400
had severe vitamin D deﬁciency (P =
0.003). In a logistic regression model, se-
vere vitamin D deﬁciency was signiﬁcantly
associated with CCS $400 (unadjusted
OR 4.3, 95% CI 1.5–12.1, P = 0.005).
This association persisted after adjusting
for age, sex, and conventional cardiovas-
cular risk factors (p-total cholesterol,
p-creatinine, HbA1c, systolic blood pres-
sure, and smoking) (4.6, 1.5–13.9, P =
0.007). Among 133 high-risk patients
with elevated NT-proBNP or CCS $400,
signiﬁcant CADwas demonstrated byMPI
or CAG in 70 patients. Of these 70
Table 1dClinical characteristics of 200 type 2 diabetic patients without a history of
cardiovascular disease
All patients
25(OH)D3
$12.5 nmol/L
25(OH)D3
,12.5 nmol/L P
n 200 181 19
Sex (male/female) 152/48 135/46 17/2 0.1
Age (years) 59 (9) 59 (9) 60 (5) 0.5
Diabetes duration (years) 32.6 (5.8) 12.5 (7.4) 15.5 (6.5) 0.1
BMI (kg/m2) 32.6 (5.8) 32.4 (5.7) 33.8 (6.3) 0.3
HbA1c (%) 7.9 (1.3) 7.8 (1.3) 8.4 (1.4) 0.05
Urinary albumin
excretion (mg/24 h) 103 (39–230) 43 (41–45) 42 (39–44) 0.2
p-Creatinine (mmol/L) 76 (18) 77 (19) 74 (14) 0.5
eGFR (mL/min/1.73 m2) 90 (25) 90 (25) 96 (24) 0.3
Systolic blood pressure
(mmHg) 130 (17) 130 (17) 129 (22) 0.8
Total cholesterol (mmol/L) 3.9 (0.9) 4.0 (0.9) 3.8 (1.1) 0.6
Current smoker (%) 59 (30) 54 (30) 5 (26) 0.7
p-NT-proBNP (ng/L) 48.7 (18.6–95.0) 45.8 (18.6–91.5) 68.6 (12.7–241.5) 0.3
CCS 183 (6–604) 170 (4–534) 638 (194–1,693) 0.02
Signiﬁcant CAD (%) 70 (35) 60 (33) 10 (53) 0.1
Vitamin D (nmol/L) 36.9 (21.9–52.1) 39.1 (27.3–54.0) 11.0 (6.3–11.8) d
Data are n (%), mean (SD), or median (interquartile range).
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patients, 10 had severe vitamin D deﬁ-
ciency. The prevalence of signiﬁcant
CAD was increased in the patients with
severe vitamin D deﬁciency, although
this was not statistically signiﬁcant (P =
0.08) (Fig. 1). In a logistic regression
model, severe vitamin D deﬁciency was
associated with signiﬁcant asymptomatic
CAD (unadjustedOR 2.24, 0.87–5.81, P =
0.097). After adjustment, the OR was 2.9
(1.02–7.66, P = 0.047). Adjustment for
interaction between vitamin D levels and
season at time of study did not change the
effect of vitamin D on CAD.
Neither moderate vitamin D deﬁciency
(p-25(OH)D3 = 12.5–24.9 nmol/L) nor
vitamin D insufﬁciency (p-25(OH)D3 =
25.0–49.9 nmol/L) was signiﬁcantly as-
sociated with CCS $400 or increased
prevalence of subclinical CAD.
CONCLUSIONSdIn this cross-sectional
study including 200 asymptomatic type 2
diabetic patients with elevated UAER and no
history of CAD, severe vitamin D deﬁciency
was associated with subclinical CAD evalu-
ated as CCS$400 andwith signiﬁcant CAD
detected by MPI or CAG. Our ﬁndings add
to those of our previous prospective study in
which low levels of vitamin D were associ-
ated with increased cardiovascular mortality
in type 2 diabetic patients who had not un-
dergone cardiovascular investigation.
CCS is a continuous measurement of
the coronary arteries atherosclerotic bur-
den, andCCShas been shown tobe strongly
correlated with histopathologic CAD (2,3).
The ﬁrst large prospective observa-
tional study of CCS in diabetic patients
and controls was performed by Raggi et al.
in 2004 (15), who demonstrated that CCS
is highly associated with all-cause mortal-
ity. Of note, low CCS in this study was
associated with a low rate of mortality sim-
ilar to that of controls. Later studies have
conﬁrmed and extended this association
in asymptomatic diabetic patients without
suspectedCVD(16–18). Inaddition, india-
betic patients with proteinuria, a threshold
(CCS$400) for clinical signiﬁcant disease
exists (19). For symptomatic patients, the
method is somewhat more controversial
(20); however, in these patients, a high
CCS has been reported to identify symp-
tomatic patients with a high risk of struc-
tural coronary artery stenosis as determined
by CAG, whereas a low CCS accurately
excluded patients with signiﬁcant coro-
nary artery stenosis (,1%) (21). Subse-
quently, CCS was suggested by Beller
(22) to be valid in risk assessment and
screening for asymptomatic CAD.
The association between a low vitamin
D level and CCS $400 seen in the cur-
rent study complements data correlating
p-25(OH)D3 to an increased prevalence
or incidence of markers of subclinical
CVD. A recent study in 1,370 primarily
nondiabetic subjects found 25(OH)D3
levels to be inversely associated with the
risk of developing CAC (7). The same
study found a trend toward an increase
in magnitude of this association among
participants with impaired kidney func-
tion. In 390 consecutive patients with
type 2 diabetes, without advanced chronic
liver or renal disease, and not taking med-
ications or supplements known to affect
vitamin D metabolism, low levels of vita-
min D were found to be strongly and in-
dependently associated with increased
carotid intima-media thickness, a marker
of subclinical CVD (23).
Our ﬁnding of an association between
low vitamin D levels and asymptomatic
signiﬁcant CAD also complements data
suggesting an association between hypo-
vitaminosis D and known CVD in the
general population (10) and in type 1 di-
abetic patients (8). In addition, a study
of 459 type 2 diabetic patients showed
a strong inverse association between
25(OH)D3 levels and prevalent CVD (9).
However, some of these patients, unlike the
patients in the current study, had a history
of CVD. Furthermore, as indicated above,
in a prospective observational follow-up
study, we found low levels of vitamin D to
independently predict cardiovascular mor-
tality among type 2 diabetic patients (11).
Unlike in the present cross-sectional study,
in which we have analyzed 25(OH)D3 in
fresh plasma samples, the samples used
for vitamin D measurements in our previ-
ous follow-up study had been stored for
many years before analysis. These patients
were not examined in regard to CVD, and
data were not available in regard to comor-
bidities, level of physical activity, and sea-
sonal variation in 25(OH)D3. We were
therefore not able to rule out the possibil-
ity that the low 25(OH)D3 levels were due
to such possible confounders. The current
study has shown that severe vitamin D
deﬁciency is associated with subclinical
CAD in 200 asymptomatic and otherwise
healthy type 2 diabetic patients. This ﬁnd-
ing was not affected by adjustment for in-
teraction between the vitamin D levels
and the season of blood sampling for
25(OH)D3 analysis (data not shown).
The exact mechanisms of action be-
hind the increased prevalence of asymp-
tomatic CAD among subjects with low
vitamin D levels are unclear. Vitamin D is
primarily known for its role in the regu-
lation of the calcium homeostasis in the
body. A growing body of evidence indi-
cates that vitamin D through activation of
the vitamin D receptor (VDR) exerts ex-
traskeletal pleiotropic effects beneﬁcial to
cardiovascular health. Activation of the
VDR is associated with suppression of
the renin-angiotensin-aldosterone system
(24), cardiac myocyte hypertrophy (25),
and vascular calciﬁcation together with
atherosclerosis-lowering, anti-inﬂammatory
(26), and immunomodulatory actions.
Clinical data show that administration
of a VDR activator causes a reduction in
serum levels of inﬂammatory markers in-
volved in the acute inﬂammatory response
(27,28). Secondary hyperparathyroidism
triggered by hypovitaminosis D can also
elicit an acute phase response and thereby
promote development of CVD, providing a
plausible explanation for how hypovita-
minosis D is a possible risk factor for
CVD. Animal models are supportive of
these considerations, where vascular cal-
ciﬁcation is prevented by calcitriol doses
sufﬁcient to correct secondary hyperpara-
thyroidism (29). Interactions between
bone and vitamin D may also mediate
increased deposition of calcium in the arte-
rial wall mediated by molecules and hor-
mones released by bone (30). However, a
recent study investigating the mechanism
by which vitamin D deﬁciency may medi-
ate increased risk of CVD found a reduced
VDR signaling to be a potential mechanism
underlying increased foam cell formation
and accelerated CVD in type 2 diabetic
Figure 1dPrevalence of signiﬁcantCADamong
all 200patients in accordancewith vitaminD level.
Black bar, 25(OH)D3 ,12.5 nmol/L; gray bar,
25(OH)D3$12.5 nmol/L.
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patients compared with nondiabetic pa-
tients (31). Figure 1 shows the prevalence
of signiﬁcant CAD among all 200 patients
according to vitamin D deﬁciency status in
our present study.Although this prevalence
is probably a minimum estimate because
not all patients underwent extensive ex-
aminations aimed at subclinical CAD, the
prevalence of signiﬁcant CAD was consid-
erably higher in the patients with severe
vitamin D deﬁciency, albeit this difference
did not reach statistical signiﬁcance. Fur-
thermore, in the logistic regression analy-
sis, severe vitamin D deﬁciency was
signiﬁcantly associated with CAD even af-
ter adjustment for known confounders,
suggesting the possibility of vitamin D
playing an independent role in the devel-
opment of CAD.
In healthy subjects, vitamin D deﬁ-
ciency mainly results from inadequate
sunlight exposure, dark skin color, and
inadequate nutritional supply of vitamin D–
containing foods. Seasonal variations in
vitamin D levels occur depending on geo-
graphic latitude and sun exposure in par-
ticular. A study of the general population
in a Northern European country showed a
seasonal variation in the prevalence of vi-
tamin D insufﬁciency of 73 and 29% dur-
ing winter and summer, respectively. The
difference for vitamin D deﬁciency was
likewise found to be 8 and 1%, respectively
(32). Furthermore, several conditions, such
as obesity, disorders of intestinal absorp-
tion, and liver or kidney function, pose an
increased risk of developing vitamin D de-
ﬁciency. However, as seen in Table 1, the
mean BMI for our patients with low vita-
min D levels was not signiﬁcantly different
compared with the patients with higher vi-
tamin D levels. There was no association
between vitamin D level and renal function
or UAER, and there was no association be-
tween CCS and UAER or eGFR. However,
all patients were selected to have normal
p-creatinine levels to avoid radiocontrast
problems (mean [SD] eGFR of 90 [25]
mL/min/1.73 m2). All patients had an ele-
vatedUAER,mostly in themicroalbuminu-
ric range. Had the range of eGFR or UAER
been wider, including normal and abnor-
mal values, it is possible there would have
been signiﬁcant associations.
International consensus is lacking in
regard to a deﬁnition of plasma vitamin D
levels representative of normal, insufﬁ-
ciency, and deﬁciency. In our study, se-
vere vitamin D deﬁciency was deﬁned as
p-25(OH)D3 ,12.5 nmol/L in both men
andwomen in correspondencewith theNa-
tional Danish guidelines at the time of the
study, but further studies are warranted to
more clearly establish physiologic and path-
ologic vitaminD levels in health anddisease.
Our study has some strengths and
limitations. This cohort of type 2 diabetic
patients underwent detailed and compre-
hensive testing including CAG to detect
asymptomatic CAD. Therefore, this study
contributes to future identiﬁcation of pa-
tients in whom aggressive investigations
and treatment aimed at CAD should be
considered. Given the cross-sectional de-
sign, the current study does not elaborate
further on the causative nature of the as-
sociations made, but it does add to an in-
creasing amount of data suggesting that
vitamin D substitution might be a potential
therapeutic mean to prevent cardiovas-
cular disease development or progression.
We did not measure parathyroid hormone
levels, and therefore we were not able to
adjust for this potential confounder in our
analysis. Prospective, randomized, placebo-
controlled trials administrating a VDR
activator are needed to examine causality
between vitamin D status and CAD in dia-
betic patients.
In conclusion, we have shown that
low levels of vitamin D are associated with
asymptomatic CAD in asymptomatic high-
risk type 2 diabetic patients with elevated
UAER.
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